non-glp 1 weight-loss medications Market Overview: GLP-1 Agonists and the Obesity Market | Blog WLP-1™: GLP-1 Benefits, No Needles,

increased cortisol levels were observed in both healthy humans and type 1 diabetes patients to whom GLP-1 had been administered peripherally [76]

Lexaria recently announced that it had extended the MTA agreement so that the partner may review the full dataset from the study

Serious Safety Concerns Associated With Saxenda Severe Gastrointestinal Motility Disorders Reported injuries include: gastroparesis (stomach paralysis) ileus (functional bowel shutdown) severe constipation chronic digestive dysfunction Related: Motility Disorders Dehydration & Kidney Injury Ongoing vomiting or reduced intake may lead to: dehydration electrolyte imbalance acute kidney injury (AKI) worsening kidney disease Related: Dehydration and Kidney Damage Gallbladder Disease Weight loss and altered bile flow may increase the risk of: gallstones gallbladder inflammation gallbladder removal surgery Related: Gallbladder Removal Pancreatitis Some patients report: severe abdominal pain elevated pancreatic enzymes hospitalization for pancreatitis Related: Pancreatitis Vision Problems / NAION Serious vision complications, including Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) , have been reported across the GLP-1 drug class

Because retatrutide is not FDA approved, some patients may be better served by approved or more established medical weight-loss options

Kannan S, Balakrishnan J, Nagarajan P

Before writing a prescription, our doctor looks over your medical history, current medications, and lab work